Aerpio Pharmaceuticals, a company focused on developing drugs to treat ocular diseases and diabetic complications, today announced top-line results
Xeris Pharmaceuticals, Inc. announced it has begun dosing patients in a Phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon
AstraZeneca’s drug Brilinta® met primary endpoints in Phase 3 trials, the company reported on Monday. The trials showed that Brilinta
StimLabs, a regenerative technology company announced that the first patient has been enrolled in the company’s clinical trial assessing the
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases
What you need to know about being part of a diabetes research study.
Get a little dLife delivered to your inbox every week.
Leave this field empty if you’re human: